Ozempic and opioid medications can both slow gastrointestinal motility. Learn how this combination may increase nausea, bloating, delayed gastric emptying, and the risk of digestive complications.
Ozempic helps patients eat less by slowing digestion, but excessive gastric emptying delays may create a hidden nutritional risk. Learn how severe fullness, nausea, and food intolerance can contribute to malnutrition during GLP-1 therapy.
Headaches, migraines, dizziness, and visual symptoms can occur during GLP-1 treatment. Learn how to distinguish common side effects from symptoms that may require medical attention.
GLP-1 medications can dramatically improve weight loss and metabolic health, but rapid fat reduction may also contribute to bile sludge, gallstones, and pancreatitis risk. Here’s what clinicians and patients need to know.
GLP-1 medications can produce dramatic weight loss, but many patients report fatigue, morning nausea, and reduced workplace performance during dose escalation. Here’s what current evidence reveals about the biology behind these symptoms — and why slower titration may improve tolerability without sacrificing results.
Rapid weight loss from GLP-1 medications like Ozempic and Wegovy may lead to muscle loss and a flattened glute appearance known as “Ozempic butt.” Learn how resistance training, protein intake, and targeted glute exercises can help preserve muscle and support healthier weight loss.
Constipation is a common yet overlooked side effect of GLP-1 medications like semaglutide. Learn why it happens, how to prevent it, and when it may signal something more serious.
Hair loss on Wegovy affects a small but notable percentage of users. This expert review explains the science behind shedding, risk factors, and recovery timelines.
Foundayo (orforglipron) is a new FDA-approved pill for adults living with obesity or extra weight tied to health problems. The highest dose led to about 12% average weight loss in a large trial. Certain thyroid, pancreas, and stomach conditions make this drug unsafe.